Lactobacillus casei PXN 37

What does the research say about Lactobacillus casei PXN 37?

2 health outcomes synthesised

Lactobacillus casei PXN 37 has been studied in the context of two health outcomes: reducing inflammation and improving quality of life, based on research syntheses covering a total of 6 studies. The strongest evidence, though still low overall, is for reducing inflammation, where all 3 studies reported beneficial effects, predominantly in patients with autoimmune diseases, neurodegenerative conditions, and depression with somatic comorbidities. No consistent effective dose has been identified across studies, and the research base remains small and preliminary.

Strongest evidence: The only outcome with evidence not rated 'very low' is reduced inflammation, where the evidence strength is low. Across all 3 studies, beneficial effects were reported, with 2 of 3 reaching statistical significance. The predominant effect size is moderate, observed primarily in patient populations with autoimmune diseases, neurodegenerative diseases (Alzheimer's, Parkinson's, multiple sclerosis, mild cognitive impairment), and depressed patients with somatic comorbidities. No effective dose range could be derived from the available data.

Mixed or weaker evidence: For improved quality of life, the evidence strength is very low. All 3 available studies are systematic reviews (not original trials), and none reported individual statistical significance specific to Lactobacillus casei PXN 37. Effect sizes were mixed (small to moderate), with the highest-quality study reporting a small benefit in colorectal cancer patients undergoing chemotherapy. No consistent dose, form, or treatment duration data were available.

Effective dose patterns: No consistent effective dose could be identified across either outcome. Doses, forms, and treatment durations were not consistently reported in the underlying studies, limiting the ability to recommend a specific intake range.

Population insights: The research suggests that benefits for inflammation may be most pronounced in people with underlying autoimmune or neurodegenerative diseases, or depression with somatic comorbidities. For quality of life, the only population showing a clear benefit was colorectal cancer patients undergoing chemotherapy, though evidence is very preliminary.

Notable caveats: Both syntheses are based on only 3 studies each, making conclusions preliminary. The clinical literature in this area is subject to publication bias — null-result studies are less likely to be published or indexed. For quality of life, all studies were reviews rather than original trials, and none reported strain-specific statistical significance. For inflammation, one study found benefit only in a subgroup (depressed patients with somatic comorbidities), suggesting effects may not be universal.

Frequently asked

What is Lactobacillus casei PXN 37 good for according to research?
Based on available research, Lactobacillus casei PXN 37 has been studied for reducing inflammation and improving quality of life. All 3 studies on inflammation reported beneficial effects, with 2 reaching statistical significance, and all 3 studies on quality of life reported benefits, though evidence strength is low to very low.
What dose of Lactobacillus casei PXN 37 is typically used in studies?
No consistent effective dose has been reported across the studies reviewed. Doses, forms (e.g., probiotic alone or as part of synbiotic supplementation), and treatment durations were not consistently reported, so no specific range can be derived from the current evidence.
Who benefits most from Lactobacillus casei PXN 37?
For inflammation, benefits were observed primarily in patients with autoimmune diseases, neurodegenerative diseases (Alzheimer's, Parkinson's, multiple sclerosis, mild cognitive impairment), and depressed patients with somatic comorbidities. For quality of life, the strongest signal was in colorectal cancer patients undergoing chemotherapy.
Are there caveats or limitations in the research on Lactobacillus casei PXN 37?
Yes, the evidence base is very small—only 3 studies per outcome—so conclusions should be considered preliminary. Publication bias is a concern (null-result studies are less likely to be published), and for quality of life, all studies were reviews, not original trials. One inflammation study found benefit only in a subgroup, suggesting effects may not be universal.
Does Lactobacillus casei PXN 37 help with inflammation?
Research suggests it may help reduce inflammation, with all 3 studies reporting beneficial effects and 2 of 3 reaching statistical significance. The evidence strength is low, and the predominant effect size is moderate, seen in patients with autoimmune, neurodegenerative, or depression-related conditions.
Is the evidence for Lactobacillus casei PXN 37's effect on quality of life reliable?
The evidence for improved quality of life is very low in strength and preliminary. All 3 studies were systematic reviews, none reported statistical significance specific to this strain, and effect sizes were mixed. The highest-quality study reported a small benefit in colorectal cancer patients, but results should be interpreted with caution.

Most-studied combinations with Lactobacillus casei PXN 37

most supplement research is combination research

Also studied with:Lactobacillus rhamnosus PXN 54 (6), Streptococcus thermophilus PXN 66 (8)